Status:
COMPLETED
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
Lead Sponsor:
GlaxoSmithKline
Conditions:
Thrombosis, Venous
Eligibility:
All Genders
18+ years
Brief Summary
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common post-operative complication. The effectiveness of fondaparinux compared with other injectabl...
Eligibility Criteria
Inclusion
- age 18 and older
- at least one record of a primary inpatient discharge diagnosis of cancer (index hospitalization)
- a procedure code for a cancer-related surgery during the index hospitalization
- a code for an anticoagulant treatment (dalteparin, enoxaparin, fondaparinux or unfractionated heparin (UFH)) as thromboprophylaxis therapy during the day prior to or two days after cancer-related surgery during the index hospitalization (this is the INDEX EVENT)
Exclusion
- a record that the patient received more than one injectable anticoagulant on Day 1 of anticoagulant therapy
- a record that the patient received anticoagulant therapy prior to index anticoagulant
- a primary diagnosis code of DVT, PE, or major bleed
- evidence of an outpatient emergency department or hospital outpatient clinic visit that included a diagnosis code for DVT or PE during the 6 months prior to the index hospitalization
- patient records for patients transferred from another facility outside Premier system on index hospitalization
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
4068 Patients enrolled
Trial Details
Trial ID
NCT01444612
Start Date
February 1 2010
End Date
November 1 2010
Last Update
May 16 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.